Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Capecitabine and Doxorubicin in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010). ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1200 participants. Primary completion is estimated at 2027-07-11. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin. Registered primary measures: Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC); PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Doxorubicin, Merck & Co. (MSD), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sacituzumab tirumotecan, TROP2, Doxorubicin, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/